<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02732704</url>
  </required_header>
  <id_info>
    <org_study_id>CP-0004</org_study_id>
    <secondary_id>P02C320_JV06EFS_CIP</secondary_id>
    <secondary_id>CA-0002 EU</secondary_id>
    <secondary_id>CA-0002 Germany</secondary_id>
    <secondary_id>CA-0011</secondary_id>
    <nct_id>NCT02732704</nct_id>
  </id_info>
  <brief_title>JenaValve Pericardial TAVR Aortic Regurgitation Study</brief_title>
  <official_title>Safety and Effectiveness/Performance of the Transapical and Transfemoral JenaValve Pericardial TAVR System in the Treatment of Patients With Symptomatic Severe Aortic Regurgitation (AR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JenaValve Technology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cardiovascular Research Foundation, New York</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>JenaValve Technology, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to collect information about a new treatment for severe
      aortic regurgitation, which affects the aortic valve in the heart. Aortic regurgitation is a
      condition where the heart's aortic valve does not close tightly and allows some blood to leak
      back into the heart chamber. Symptoms of aortic regurgitation may include fatigue and
      shortness of breath. The preferred treatment for severe aortic regurgitation is aortic valve
      replacement surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will examine the use of TAVR (Transcatheter Aortic Valve Replacement), which is a
      minimally invasive procedure designed to replace the aortic valve inside the heart. The
      JenaValve Pericardial TAVR System will be examined in this clinical study for aortic valve
      replacement. The TAVR procedure is performed by a heart surgeon and/or an interventional
      cardiologist. A less invasive surgical approach called TAVR is offered to those patients who
      are high risk for undergoing open heart surgery to replace the aortic valve. In this study,
      TAVR will be performed using the JenaValve Pericardial TAVR System, which is intended to help
      treat severe aortic regurgitation. The JenaValve replacement valve is placed inside the
      aortic valve by using the JenaValve delivery system. The JenaValve replacement valve may be
      implanted in one of two ways: (1) transapical - where the valve is implanted through the
      chest wall, and (2) transfemoral - where the valve is implanted through an artery in the
      groin. The choice of which implant method will be used is decided by the doctor.The choice of
      which approach is used is at the clinical discretion of the study physicians. The TAVR
      procedure typically takes 1-2 hours to complete. The JenaValve TAVR device, once implanted,
      is designed to remain permanently in place.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-Cause Mortality Rate at 30 Days</measure>
    <time_frame>30 days</time_frame>
    <description>All-cause mortality rate at 30 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event rate of VARC-2 Individual Safety Endpoints</measure>
    <time_frame>2 to 5 years</time_frame>
    <description>Event rate of VARC-2 Individual Safety Endpoints procedurally to 30 days, 6 months, 1 year and annually up to 5 years (US) and 2 years (OUS) for the following:
All-cause mortality
Myocardial infarction
Neurological Complications - All-cause stroke and transient ischemic attack (TIA)
Bleeding Complications
Acute kidney injury (AKIN classification within 7 days post-index procedure)
Vascular Complications (Major, minor, closure device failure)
Conduction Disturbances and Arrhythmias
TAVR-related complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcomes through 5 years (US) and to 2 year follow up (OUS) - KCCQ</measure>
    <time_frame>2 to 5 years</time_frame>
    <description>Number of patients with improvement vs. baseline in symptoms measured by:
- Improvement vs. baseline in Quality of Life, per Kansas City Cardiomyopathy Questionnaire (KCCQ greater than 10 from baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcomes through 5 years (US) and to 2 year follow up (OUS) - NYHA Class</measure>
    <time_frame>2 to 5 years</time_frame>
    <description>Number of patients with improvement vs. baseline in symptoms measured by:
- NYHA Class greater than 1 over baseline, or NYHA Class less than III or IV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcomes through 5 years (US) and to 2 year follow up (OUS) - 6MWT</measure>
    <time_frame>2 to 5 years</time_frame>
    <description>Number of patients with improvement vs. baseline in symptoms measured by:
- Improvement vs. baseline in functional status using six minute walk test (6MWT) improvement greater than 50 feet from baseline</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Device Success</measure>
    <time_frame>2 to 5 Years</time_frame>
    <description>Number of patients alive and stroke free with the originally intended device in place, no surgical or interventional procedures related to access or the device, and with intended device performance at 30 days, 6 months, 1 year, and 2 years (OUS) and up to 5 years (US)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Aortic Regurgitation</condition>
  <arm_group>
    <arm_group_label>transcatheter aortic valve replacement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this study, transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve Pericardial TAVR System, which is intended to help treat severe aortic regurgitation. The JenaValve replacement valve is placed inside the aortic valve by using the JenaValve delivery system.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>JenaValve Pericardial TAVR System</intervention_name>
    <description>In this study, transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve Pericardial TAVR System, which is intended to help treat severe aortic regurgitation. The JenaValve replacement valve is placed inside the aortic valve by using the JenaValve delivery system.</description>
    <arm_group_label>transcatheter aortic valve replacement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with severe aortic regurgitation (AR).

          -  Patient at high risk for open surgical valve replacement

          -  Patient symptomatic according to NYHA functional class II or higher

        Exclusion Criteria:

          -  Congenital uni- or bicuspid aortic valve morphology

          -  Previous prosthetic aortic valve (bioprosthesis or mechanical) implant

          -  Endocarditis or other active infection

          -  Need for urgent or emergent TAVR procedure for any reason

          -  Cardiogenic shock or hemodynamic instability requiring inotropic support or
             ventricular assist device
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin B Leon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>NewYork-Presbyterian/Columbia University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susheel Kodali, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vinod Thourani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephan Baldus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herzzentrum der Universität zu Köln</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univiersitäts Herzzentrum Freiburg Bad Krozingen</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>6120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäres Herzzentrum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum der Universität zu Köln</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch- Krankenhaus Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <zip>1105</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus University Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <zip>3210</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2016</study_first_submitted>
  <study_first_submitted_qc>April 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2016</study_first_posted>
  <last_update_submitted>June 16, 2017</last_update_submitted>
  <last_update_submitted_qc>June 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic Valve Disease</keyword>
  <keyword>Aortic Regurgitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

